CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2025	Sep. 30, 2024	Sep. 30, 2025	Sep. 30, 2024	Dec. 31, 2024
Income Statement [Abstract]
Net revenues	$ 167,204	$ 155,095	$ 481,003	$ 443,954	$ 605,220
Cost of revenues	44,729	35,372	124,722	103,715	137,181
Gross profit	122,475	119,723	356,281	340,239	468,039
Operating costs and expenses:
Research, development and clinical studies	54,029	51,882	163,639	158,435	209,645
Sales and marketing	58,546	59,830	171,404	171,652	239,063
General and administrative	45,921	40,103	134,645	117,344	189,827
Total operating costs and expenses	158,496	151,815	469,688	447,431	638,535
Operating income (loss)	(36,021)	(32,092)	(113,407)	(107,192)	(170,496)
Financial income (expenses), net	5,999	10,507	18,111	31,236	39,334
Income (loss) before income tax	(30,022)	(21,585)	(95,296)	(75,956)	(131,162)
Income tax	7,248	8,985	16,432	26,749	37,465
Net income (loss)	$ (37,270)	$ (30,570)	$ (111,728)	$ (102,705)	$ (168,627)
Basic net income (loss) per ordinary share	$ (0.33)	$ (0.28)	$ (1.00)	$ (0.95)	$ (1.56)
Diluted net income (loss) per ordinary share	$ (0.33)	$ (0.28)	$ (1.00)	$ (0.95)	$ (1.56)
Weighted average number of ordinary shares used in computing basic net income (loss) per share (in shares)	111,908,252	108,247,716	111,259,532	107,679,501	107,834,368
Weighted average number of ordinary shares used in computing diluted net income (loss) per share (in shares)	111,908,252	108,247,716	111,259,532	107,679,501	107,834,368